IGF OT IGF TO DEVELOP HEMODEFEND HEMOCOMPATIBLE HIGHLY POROUS POLYMER BEADS OPTIMIZED TO BROADLY REMOVE FREEHEMOGLOBIN POTASSIUM REACTIVE ANTIBODIES AND INFLAMMATORY OR REACTIVE SUBSTANCES FROM

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

• Novel Oral Sorbent Therapy for the Prevention and Treatment of Traveler’s Diarrhea
• Novel Sorbent Technology for the Rapid Treatment of Acute Joint Injury and Inflammation
• Novel Extracorporeal Therapy for the Reversal of Septic Shock and Restoring Hemodynamic Stability
• Investigation of a potassium adsorber for the treatment of hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine
• Development of an Effective Adsorber to Remove Anti-A and Anti-B Antibodies from Plasma for Transfusion

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

• DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
• Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
• Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
• The Next Wave of Asthma Therapeutics
• Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications

Research funding history

16 SBIR/STTR records share this UEI (2012–2023). Reported award amounts total $11,830,667. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards